{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:07:32Z","timestamp":1772107652065,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.parkreldis.2015.08.030","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T21:11:42Z","timestamp":1440796302000},"page":"1238-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Patompong","family":"Ungprasert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narat","family":"Srivali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2015.08.030_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/NRL.0b013e318251e6f2","article-title":"Clinical characteristics of exacerbations in Parkinson disease","volume":"18","author":"Zheng","year":"2012","journal-title":"Neurologist"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2012.11.014","article-title":"Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease","volume":"62","author":"Yan","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/187152707783399201","article-title":"Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases","volume":"6","author":"Nunomura","year":"2007","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.abb.2004.03.006","article-title":"Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma","volume":"430","author":"Yeum","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","article-title":"Uric acid as a CNS antioxidant","volume":"19","author":"Bowman","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0361-9230(94)90285-2","article-title":"Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation","volume":"33","author":"Church","year":"1994","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/oxfordjournals.aje.a008954","article-title":"Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease","volume":"144","author":"Davis","year":"1996","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.20663","article-title":"Serum uric acid levels and the risk of Parkinson disease","volume":"58","author":"De Lau","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","article-title":"Plasma urate and risk of Parkinson's disease","volume":"166","author":"Weisskopf","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib14","first-page":"43","article-title":"Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease","volume":"75","author":"Larumbe Ilundain","year":"2001","journal-title":"Rev. Esp. Salud. Publica"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.21502","article-title":"Low plasma uric acid level in Parkinson's disease","volume":"22","author":"Annanmaki","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1742-1241.2009.02188.x","article-title":"Update on gout and hyperuricemia","volume":"64","author":"Baker","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.wnl.0000279518.10072.df","article-title":"Gout and risk of Parkinson disease: a prospective study","volume":"69","author":"Alonso","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10654-013-9791-1","article-title":"Gout and the risk of Parkinson's disease in Denmark","volume":"28","author":"Schernhammer","year":"2013","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijge.2013.01.006","article-title":"Gout and Parkinson's disease in older people: an observation in Taiwan","volume":"8","author":"Lai","year":"2014","journal-title":"Int. J. Gerontol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib20","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.24193","article-title":"Gout and the risk of Parkinson's disease: a cohort study","volume":"59","author":"De Vera","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12883-015-0273-9","article-title":"Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: a record-linkage studies","volume":"15","author":"Pakpoor","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trial"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/brain\/awn316","article-title":"Serum uric acid and cognitive function and dementia","volume":"132","author":"Euser","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1871527314666150430161659","article-title":"Lower uric acid linked with cognitive dysfunction in the elderly","volume":"14","author":"Mendez-Hernandez","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.parkreldis.2015.08.030_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1179\/1743132811Y.0000000074","article-title":"Serum uric acid levels in patients with multiple sclerosis: a meta-analysis","volume":"34","author":"Liu","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib29","doi-asserted-by":"crossref","first-page":"852954","DOI":"10.1155\/2014\/852954","article-title":"Review of hyperuricemia as new marker for metabolic syndrome","volume":"2014","author":"Billiet","year":"2014","journal-title":"ISRN Rheumatol."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/SMJ.0000000000000082","article-title":"Hyperuricemia, gout and related comorbidities: cause and effect on a two-way street","volume":"107","author":"Karis","year":"2014","journal-title":"South Med. J."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib31","doi-asserted-by":"crossref","first-page":"729194","DOI":"10.1155\/2014\/729194","article-title":"Metabolic syndrome: an important risk factor for Parkinson's disease","volume":"2014","author":"Zhang","year":"2014","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.23384","article-title":"Cysteinyl-glycine reduction as marker for Levodopa-induced oxidative stress in Parkinson's disease patients","volume":"26","author":"Muller","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2015.08.030_bib33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00702-013-1155-1","article-title":"Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients","volume":"121","author":"Muller","year":"2014","journal-title":"J.\u00a0Neural. Transm."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015003697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802015003697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T23:48:57Z","timestamp":1567122537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015003697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1353802015003697"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.08.030","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2015.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}